XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Business Segments and Geographic Information
 6 Months Ended
Mar. 27, 2021
Segment Reporting [Abstract]  
Business Segments and Geographic Information Business Segments and Geographic InformationDuring fiscal 2021, the Company had four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. During fiscal 2020, the Company had five reportable segments that included Medical Aesthetics. The Company completed the sale of its Medical Aesthetics business on December 30, 2019. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, transaction and integration
expenses for acquisitions, restructuring, consolidation and divestiture charges, litigation charges, and other one-time or unusual items.
Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and six months ended March 27, 2021 and March 28, 2020. Segment information is as follows:
 Three Months EndedSix Months Ended
 March 27,
2021		March 28,
2020		March 27,
2021		March 28,
2020
Total revenues:
Diagnostics$1,064.5 $319.2 $2,192.7 $630.7 
Breast Health336.3 307.8 669.1 638.9 
GYN Surgical114.2 105.4 238.2 224.5 
Skeletal Health22.6 23.7 47.4 47.2 
Medical Aesthetics— — — 65.3 
$1,537.6 $756.1 $3,147.4 $1,606.6 
Income from operations:
Diagnostics$700.6 $57.3 $1,485.0 $106.8 
Breast Health67.8 75.9 154.1 169.8 
GYN Surgical28.6 23.9 42.3 55.4 
Skeletal Health(0.2)1.7 0.8 2.6 
Medical Aesthetics— (2.4)— (53.4)
$796.8 $156.4 $1,682.2 $281.2 
Depreciation and amortization:
Diagnostics$59.1 $59.3 $115.4 $118.4 
Breast Health12.9 13.1 26.0 23.1 
GYN Surgical23.0 21.1 46.3 42.1 
Skeletal Health0.2 0.2 0.3 0.4 
Medical Aesthetics— — — 4.1 
$95.2 $93.7 $188.0 $188.1 
Capital expenditures:
Diagnostics$39.3 $17.1 $77.6 $35.3 
Breast Health2.7 8.1 5.6 14.5 
GYN Surgical3.2 5.3 6.5 10.6 
Skeletal Health— 0.1 — 0.2 
Medical Aesthetics— — — 1.4 
Corporate0.6 1.1 0.9 1.1 
$45.8 $31.7 $90.6 $63.1 
 
March 27,
2021		September 26,
2020
Identifiable assets:
Diagnostics$2,584.1 $2,161.4 
Breast Health1,266.8 1,200.9 
GYN Surgical1,402.3 1,438.7 
Skeletal Health30.4 38.9 
Corporate2,760.4 2,355.9 
$8,044.0 $7,195.8 
The Company had no customers that represented greater than 10% of consolidated revenues during the three and six months ended March 27, 2021 and March 28, 2020.
The Company operates in the following major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, the United Kingdom and Germany. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of world” designation includes Canada, Latin America and the Middle East.
Revenues by geography as a percentage of total revenues were as follows:
 
 Three Months EndedSix Months Ended
 March 27,
2021		March 28,
2020		March 27,
2021		March 28,
2020
United States69.2 %76.0 %70.0 %75.1 %
Europe21.9 %14.8 %21.4 %13.8 %
Asia-Pacific5.9 %5.5 %5.7 %7.0 %
Rest of World3.0 %3.7 %2.9 %4.1 %
100.0 %100.0 %100.0 %100.0 %